"Your health is our #1 Priority. Medvin Clinical Research is a multi-specialty, multi-facility Research Company based in Los Angeles, California that has been conducting clinical trials in Rheumatology, Gastroenterology, Cardiology and Internal medicine among other indications since 2006. We have successfully completed in excess of 130 trials and helped over a 3000 patients achieve the quality of life that they deserve. People who enroll in these clinical studies often get better medical care than most other patients, can get an advanced therapy that generally is not available to other patients and receive follow-up monitoring to assure their safety."

During the past decade, Medvin Clinical Research conducted 44 clinical trials. In the 10-year time frame, 44 clinical trials started and 35 clinical trials were completed, i.e. on average, 79.5% percent of trials that started reached the finish line to date. In the past 5 years, 18 clinical trials started and 23 clinical trials were completed. i.e. 127.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Medvin Clinical Research" #1 sponsor was "Pfizer" with 9 trials, followed by "Eli Lilly and Company" with 7 trials sponsored, "Hoffmann-La Roche" with 4 trials sponsored, "Janssen Research & Development, LLC" with 4 trials sponsored and "Gilead Sciences" with 4 trials sponsored. Other sponsors include 22 different institutions and companies that sponsored additional 27 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Medvin Clinical Research" #1 collaborator was "Incyte Corporation" with 4 trials as a collaborator, "Galapagos NV" with 3 trials as a collaborator, "OCT Clinical Trials" with 3 trials as a collaborator, "Quintiles, Inc." with 2 trials as a collaborator and "CTI Clinical Trial and Consulting Services" with 1 trials as a collaborator. Other collaborators include 5 different institutions and companies that were collaborators in the rest 15 trials.

According to Clinical.Site data, the most researched conditions in "Medvin Clinical Research" are "Rheumatoid Arthritis" (14 trials), "Arthritis, Rheumatoid" (6 trials), "Psoriatic Arthritis" (5 trials), "Systemic Lupus Erythematosus" (5 trials) and "Osteoarthritis, Hip" (4 trials). Many other conditions were trialed in "Medvin Clinical Research" in a lesser frequency.

Most popular intervention types in "Medvin Clinical Research" are "Drug" (48 trials), "Biological" (8 trials), "Other" (7 trials), "Device" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (20 trials), "Baricitinib" (5 trials), "Filgotinib" (4 trials), "Adalimumab" (3 trials) and "Placebo to match filgotinib" (3 trials). Other intervention names were less common.

The vast majority of trials in "Medvin Clinical Research" are 54 trials for "All" genders.

Currently, there are NaN active trials in "Medvin Clinical Research". undefined are not yet recruiting, 8 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 28 completed trials in Medvin Clinical Research, undefined suspended trials, and 13 terminated clinical trials to date.

Out of the total trials that were conducted in Medvin Clinical Research, 0 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 29 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 9 trials, and there were also 2 trials that are defined as “Not Applicable".